Sinocare(SZ:300298)2022-12-07 09:38Product Development - The company launched new products including the Anyi, smart, and mobile blood glucose meters in 2014 [3] - In November 2014, the company obtained registration certificates for its gold series products, expanding its product offerings to meet diverse customer needs [3] - Ongoing research includes POCT products for chronic diseases like diabetes and diabetic nephropathy, focusing on indicators such as blood ketones, creatinine, and glycosylated hemoglobin [3] Mobile Healthcare and Technology - The company views mobile healthcare as a future trend and is currently in the exploratory phase, aiming to provide better services through data sharing [3] - The goal is to establish a systematic platform to enhance customer service and support chronic disease management [4] Hospital Market Development - The company has formed a hospital team of over 40 members since last year, with products entering some hospitals, although sales remain limited [4] - Current products in the hospital market include the EA-11 dual-function blood glucose and uric acid testing system and microalbumin tests [4] Market Barriers - Barriers to entering the hospital market include the need to improve the reputation and influence of domestic brands and to gain the trust of healthcare professionals [5] Future Growth Points - The company has established a sales system with over 1,000 distributors and more than 40,000 retail terminals, which is gradually stabilizing [6] - Future market expansion efforts will focus on international markets and the hospital sector, which are expected to be the main growth drivers [6] Export Performance - The company has disclosed export orders exceeding $860,000 for the year, with revenue confirmation dependent on annual shipments and confirmations from clients [6]